Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Monday, February 19, 2018
 
Recommended for you
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
FiercePharma • Eric Sagonowsky
Krasner, feds announce initiatives to combat opioid crisis
Philadelphia Inquirer
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Johnson & Johnson Investors (JNJ)
BusinessWire
Janssen Gets FDA Approval for New Prostate Cancer Drug
Equities.com • Equities Research
Apalutamide (Johnson & Johnson) Drug Analysis 2018: An Orally Available Androgen Signaling Inhibitor - ResearchAndMarkets.com
BusinessWire
Managing Product Recalls: What to Do After a Recall
The National Law Review • Schiff Hardin Llp
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson
BusinessWire
Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows
FiercePharma • Arlene Weintraub
Johnson & Johnson company closing Alabama facility, cutting 150 jobs
The Business Journals • Hanno Van Der Bijl
Why I Recently Bought Johnson & Johnson
Seeking Alpha • Big Ticket Fund Managers
 
Recommended for You
Johnson & Johnson, Merck & Co., Inc.
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
FiercePharmaEric Sagonowsky
Pfizer hasn't gained much market share with Inflectra, its biosimilar of Johnson & Johnson's Remicade, since its U.S. launch back in 2016. The company's CEO Ian Read recently said Inflectra is picking up increased commercial coverage, but an analyst figures the biosimilar's...
Share
Johnson & Johnson, Pharmaceuticals
Krasner, feds announce initiatives to combat opioid crisis
Philadelphia Inquirer
Buy Photo On the heels of a lawsuit filed Jan. 17 by Philadelphia city officials against 10 pharmaceutical companies claiming that misleading marketing methods have fueled the city’s opioid crisis, District Attorney Larry Krasner announced Thursday that he had filed his own...
Share
Johnson & Johnson
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Johnson & Johnson Investors (JNJ)
BusinessWire
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in...
Share
Cancer, Johnson & Johnson
Janssen Gets FDA Approval for New Prostate Cancer Drug
Equities.comEquities Research
According to the American Cancer Society, nearly 165,000 new cases of prostate cancer will be diagnosed this year, with over 29,000 deaths as a result. About 1 man in 9 will be diagnosed with prostate cancer during his lifetime. Patients with non-metastatic...
Share
Cancer, Johnson & Johnson
Apalutamide (Johnson & Johnson) Drug Analysis 2018: An Orally Available Androgen Signaling Inhibitor - ResearchAndMarkets.com
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Apalutamide" drug pipelines has been added to ResearchAndMarkets.com's offering. Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its...
Share
Brand Management, Johnson & Johnson
Managing Product Recalls: What to Do After a Recall
The National Law ReviewSchiff Hardin Llp
If a company facing a recall has managed it effectively, the hardest part is probably over. After writing about how companies can prepare for and manage an effective recall, here are strategies companies can use to restore order and maintain brand loyalty...
Share
Johnson & Johnson, Law
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson
BusinessWire
NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson (NYSE: JNJ) concerning possible violations of federal securities laws. On February 5, 2018, CNBC published an article alleging that current “court proceedings could expose potentially damaging...
Share
Johnson & Johnson, Medical Science & Research
Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows
FiercePharmaArlene Weintraub
Just after New Year’s, in an announcement that was easy to overlook in the post-holiday haze, Johnson & Johnson’s Janssen Pharmaceutical celebrated an historic FDA approval. The agency cleared new label language for the company’s 9-year-old schizophrenia treatment, Invega Sustenna, stating that...
Share
Johnson & Johnson
Johnson & Johnson company closing Alabama facility, cutting 150 jobs
The Business JournalsHanno Van Der Bijl
A Johnson & Johnson company is closing its facility in Russell County. Vogue International will be shutting down its 550,000-square-foot distribution center in Phenix City by April 30, reports the Ledger-Enquirer. The move will mean a loss of 150 jobs for the...
Share
Actelion Pharmaceuticals, Finance
Why I Recently Bought Johnson & Johnson
Seeking AlphaBig Ticket Fund Managers
Summary Recently initiated a position in JNJ at $129. Take advantage of the recent dip in a blue chip dividend aristocrat. Recent earnings have renewed my trust in the company's long term growth plan backed by a strong pipeline that will fuel...
Share